Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry

Yan Xu, Bruce Keith, Jean L. Grem

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

A liquid chromatography/mass spectrometry (LC-MS) method has been developed and validated for the determination of the anticancer agent gemcitabine (dFdC) and its metabolite 2′,2′-difluoro-2′- deoxyuridine (dFdU) in human plasma. An Oasis® HLB solid phase extraction cartridge was used for plasma sample preparation. Separation of the analytes was achieved with a YMC ODS-AQ (5μm, 120Å, 2.0mm×150mm) column. The initial composition of the mobile phase was 2% methanol/98% 5mM ammonium acetate at pH 6.8 (v/v), and the flow rate was 0.2ml/min. An isocratic gradient was used for 3min, followed by a linear gradient over 4min to 30% methanol/70% 5mM ammonium acetate at pH 6.8. The gradient returned to the initial conditions over 2min and remained there for 6min. The retention times of dFdC, dFdU, and the internal standard 5′-deoxy-5-fluorouridine (5′-DFUR) were 11.46, 12.63, and 13.58min. The mass spectrometer was operated under negative electrospray ionization conditions. Single-ion- monitoring (SIM) mode was used for analyte quantitation at m/z 262 for [dFdC-H]-, m/z 263 for [dFdU-H]-, and m/z 245 for [5′-DFUR-H]-. The average recoveries for dFdC, dFdU, and 5′-DFUR were 88.4, 84.6, and 99.3%, respectively. The linear calibration ranges were 5-1000ng/ml for dFdC, and 5-5000ng/ml for dFdU. The intra- and inter-assay precisions (%CV) were ≤3 and ≤7% at three concentration levels (50.0, 500, and 5000ng/ml). The limits of quantitation (defined as 10 times of signal-to-noise ratio) were 3.16ng/ml for dFdC, and 1.35ng/ml for dFdU with 50-μl sample injections. This method has been used for measuring plasma concentrations of dFdC and dFdU in samples from adult cancer patients in a Phase I trial of weekly dFdC given as 150 (or lower) mg/(m2 24-h) infusion. The average plasma dFdC concentrations at 22- and 23-h into the infusion were 18.3 and 16.8ng/ml at 150 and 100mg/m2, respectively; the values for dFdU averaged 2950 and 1372ng/ml.

Original languageEnglish (US)
Pages (from-to)263-270
Number of pages8
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume802
Issue number2
DOIs
StatePublished - Apr 5 2004

Fingerprint

gemcitabine
Plasma (human)
Deoxyuridine
Liquid chromatography
Metabolites
Liquid Chromatography
Antineoplastic Agents
Mass spectrometry
Mass Spectrometry
Plasmas
Methanol
Assays
Electrospray ionization
Solid Phase Extraction
Signal-To-Noise Ratio
Mass spectrometers
Calibration
Signal to noise ratio

Keywords

  • 2′,2′-Difluoro-2′-deoxyuridine
  • Gemcitabine

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Clinical Biochemistry
  • Cell Biology

Cite this

@article{9a4d790fc8f24b0eb84861ac57203c11,
title = "Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry",
abstract = "A liquid chromatography/mass spectrometry (LC-MS) method has been developed and validated for the determination of the anticancer agent gemcitabine (dFdC) and its metabolite 2′,2′-difluoro-2′- deoxyuridine (dFdU) in human plasma. An Oasis{\circledR} HLB solid phase extraction cartridge was used for plasma sample preparation. Separation of the analytes was achieved with a YMC ODS-AQ (5μm, 120{\AA}, 2.0mm×150mm) column. The initial composition of the mobile phase was 2{\%} methanol/98{\%} 5mM ammonium acetate at pH 6.8 (v/v), and the flow rate was 0.2ml/min. An isocratic gradient was used for 3min, followed by a linear gradient over 4min to 30{\%} methanol/70{\%} 5mM ammonium acetate at pH 6.8. The gradient returned to the initial conditions over 2min and remained there for 6min. The retention times of dFdC, dFdU, and the internal standard 5′-deoxy-5-fluorouridine (5′-DFUR) were 11.46, 12.63, and 13.58min. The mass spectrometer was operated under negative electrospray ionization conditions. Single-ion- monitoring (SIM) mode was used for analyte quantitation at m/z 262 for [dFdC-H]-, m/z 263 for [dFdU-H]-, and m/z 245 for [5′-DFUR-H]-. The average recoveries for dFdC, dFdU, and 5′-DFUR were 88.4, 84.6, and 99.3{\%}, respectively. The linear calibration ranges were 5-1000ng/ml for dFdC, and 5-5000ng/ml for dFdU. The intra- and inter-assay precisions ({\%}CV) were ≤3 and ≤7{\%} at three concentration levels (50.0, 500, and 5000ng/ml). The limits of quantitation (defined as 10 times of signal-to-noise ratio) were 3.16ng/ml for dFdC, and 1.35ng/ml for dFdU with 50-μl sample injections. This method has been used for measuring plasma concentrations of dFdC and dFdU in samples from adult cancer patients in a Phase I trial of weekly dFdC given as 150 (or lower) mg/(m2 24-h) infusion. The average plasma dFdC concentrations at 22- and 23-h into the infusion were 18.3 and 16.8ng/ml at 150 and 100mg/m2, respectively; the values for dFdU averaged 2950 and 1372ng/ml.",
keywords = "2′,2′-Difluoro-2′-deoxyuridine, Gemcitabine",
author = "Yan Xu and Bruce Keith and Grem, {Jean L.}",
year = "2004",
month = "4",
day = "5",
doi = "10.1016/j.jchromb.2003.11.038",
language = "English (US)",
volume = "802",
pages = "263--270",
journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",
issn = "1570-0232",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry

AU - Xu, Yan

AU - Keith, Bruce

AU - Grem, Jean L.

PY - 2004/4/5

Y1 - 2004/4/5

N2 - A liquid chromatography/mass spectrometry (LC-MS) method has been developed and validated for the determination of the anticancer agent gemcitabine (dFdC) and its metabolite 2′,2′-difluoro-2′- deoxyuridine (dFdU) in human plasma. An Oasis® HLB solid phase extraction cartridge was used for plasma sample preparation. Separation of the analytes was achieved with a YMC ODS-AQ (5μm, 120Å, 2.0mm×150mm) column. The initial composition of the mobile phase was 2% methanol/98% 5mM ammonium acetate at pH 6.8 (v/v), and the flow rate was 0.2ml/min. An isocratic gradient was used for 3min, followed by a linear gradient over 4min to 30% methanol/70% 5mM ammonium acetate at pH 6.8. The gradient returned to the initial conditions over 2min and remained there for 6min. The retention times of dFdC, dFdU, and the internal standard 5′-deoxy-5-fluorouridine (5′-DFUR) were 11.46, 12.63, and 13.58min. The mass spectrometer was operated under negative electrospray ionization conditions. Single-ion- monitoring (SIM) mode was used for analyte quantitation at m/z 262 for [dFdC-H]-, m/z 263 for [dFdU-H]-, and m/z 245 for [5′-DFUR-H]-. The average recoveries for dFdC, dFdU, and 5′-DFUR were 88.4, 84.6, and 99.3%, respectively. The linear calibration ranges were 5-1000ng/ml for dFdC, and 5-5000ng/ml for dFdU. The intra- and inter-assay precisions (%CV) were ≤3 and ≤7% at three concentration levels (50.0, 500, and 5000ng/ml). The limits of quantitation (defined as 10 times of signal-to-noise ratio) were 3.16ng/ml for dFdC, and 1.35ng/ml for dFdU with 50-μl sample injections. This method has been used for measuring plasma concentrations of dFdC and dFdU in samples from adult cancer patients in a Phase I trial of weekly dFdC given as 150 (or lower) mg/(m2 24-h) infusion. The average plasma dFdC concentrations at 22- and 23-h into the infusion were 18.3 and 16.8ng/ml at 150 and 100mg/m2, respectively; the values for dFdU averaged 2950 and 1372ng/ml.

AB - A liquid chromatography/mass spectrometry (LC-MS) method has been developed and validated for the determination of the anticancer agent gemcitabine (dFdC) and its metabolite 2′,2′-difluoro-2′- deoxyuridine (dFdU) in human plasma. An Oasis® HLB solid phase extraction cartridge was used for plasma sample preparation. Separation of the analytes was achieved with a YMC ODS-AQ (5μm, 120Å, 2.0mm×150mm) column. The initial composition of the mobile phase was 2% methanol/98% 5mM ammonium acetate at pH 6.8 (v/v), and the flow rate was 0.2ml/min. An isocratic gradient was used for 3min, followed by a linear gradient over 4min to 30% methanol/70% 5mM ammonium acetate at pH 6.8. The gradient returned to the initial conditions over 2min and remained there for 6min. The retention times of dFdC, dFdU, and the internal standard 5′-deoxy-5-fluorouridine (5′-DFUR) were 11.46, 12.63, and 13.58min. The mass spectrometer was operated under negative electrospray ionization conditions. Single-ion- monitoring (SIM) mode was used for analyte quantitation at m/z 262 for [dFdC-H]-, m/z 263 for [dFdU-H]-, and m/z 245 for [5′-DFUR-H]-. The average recoveries for dFdC, dFdU, and 5′-DFUR were 88.4, 84.6, and 99.3%, respectively. The linear calibration ranges were 5-1000ng/ml for dFdC, and 5-5000ng/ml for dFdU. The intra- and inter-assay precisions (%CV) were ≤3 and ≤7% at three concentration levels (50.0, 500, and 5000ng/ml). The limits of quantitation (defined as 10 times of signal-to-noise ratio) were 3.16ng/ml for dFdC, and 1.35ng/ml for dFdU with 50-μl sample injections. This method has been used for measuring plasma concentrations of dFdC and dFdU in samples from adult cancer patients in a Phase I trial of weekly dFdC given as 150 (or lower) mg/(m2 24-h) infusion. The average plasma dFdC concentrations at 22- and 23-h into the infusion were 18.3 and 16.8ng/ml at 150 and 100mg/m2, respectively; the values for dFdU averaged 2950 and 1372ng/ml.

KW - 2′,2′-Difluoro-2′-deoxyuridine

KW - Gemcitabine

UR - http://www.scopus.com/inward/record.url?scp=1342285674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342285674&partnerID=8YFLogxK

U2 - 10.1016/j.jchromb.2003.11.038

DO - 10.1016/j.jchromb.2003.11.038

M3 - Article

C2 - 15018786

AN - SCOPUS:1342285674

VL - 802

SP - 263

EP - 270

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

SN - 1570-0232

IS - 2

ER -